Michael R Jacobs

List of Publications by Year
in descending order

92 papers	4,034 citations	101543 36 h-index	128289 60 g-index
97 all docs	97 docs citations	97 times ranked	3888 citing authors

#	Article	IF	Citations
1	The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. Journal of Antimicrobial Chemotherapy, 2003, 52, 229-246.	3.0	417
2	Can Ceftazidime-Avibactam and Aztreonam Overcome Î²-Lactam Resistance Conferred by Metallo-Î²-Lactamases in Enterobacteriaceae?. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	217
3	Multicenter Clinical and Molecular Epidemiological Analysis of Bacteremia Due to Carbapenem-Resistant Enterobacteriaceae (CRE) in the CRE Epicenter of the United States. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	178
4	Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance. Blood, 2016, 127, 496-502.	1.4	165
5	Relationship between Bacterial Load, Species Virulence, and Transfusion Reaction with Transfusion of Bacterially Contaminated Platelets. Clinical Infectious Diseases, 2008, 46, 1214-1220.	5.8	156
6	Parabacteroides distasonis: intriguing aerotolerant gut anaerobe with emerging antimicrobial resistance and pathogenic and probiotic roles in human health. Gut Microbes, 2021, 13, 1922241.	9.8	139
7	Surveillance of Carbapenem-Resistant Klebsiella pneumoniae: Tracking Molecular Epidemiology and Outcomes through a Regional Network. Antimicrobial Agents and Chemotherapy, 2014, 58, 4035-4041.	3.2	132
8	Detection of bacterial contamination in prestorage cultureâ€negative apheresis platelets on day of issue with the Pan Genera Detection test. Transfusion, 2011, 51, 2573-2582.	1.6	119
9	Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using Î²-Lactamase Inhibitors and Î²-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234. Journal of Medicinal Chemistry, 2018, 61, 4067-4086.	6.4	117
10	Activity of CP 99, 219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepaloxacin against penicillin-susceptible and -resistant pneumococci. Journal of Antimicrobial Chemotherapy, 1995, 35, 230-232.	3.0	108
11	Evolution of surveillance methods for detection of bacterial contamination of platelets in a university hospital, 1991 through 2004. Transfusion, 2006, 46, 719-730.	1.6	84
12	ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum Î²-Lactamases and Carbapenemases. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	81
13	Genome dynamics of multidrug-resistant Acinetobacter baumannii during infection and treatment. Genome Medicine, 2016, 8, 26.	8.2	77
14	Changes in Serotypes and Antimicrobial Susceptibility of Invasive Streptococcus pneumoniae Strains in Cleveland: a Quarter Century of Experience. Journal of Clinical Microbiology, 2008, 46, 982-990.	3.9	71
15	Corynebacterium striatum: A Diphtheroid with Pathogenic Potential. Clinical Infectious Diseases, 1993, 17, 21-25.	5.8	67
16	Adhesion ofStaphylococcus epidermidis to biomedical polymers: Contributions of surface thermodynamics and hemodynamic shear conditions. Journal of Biomedical Materials Research Part B, 1995, 29, 485-493.	3.1	66
17	Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent Î²-Lactamâ˜Î²-Lactamase Inhibitor Combination. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	65
18	Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone Î²-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent. MBio, 2019, 10, .	4.1	64

#	Article	IF	Citations
19	Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemaseâ€“4 and New Delhi Metallo-Î²-Lactamaseâ€“1. Clinical Infectious Diseases, 2020, 71, 1095-1098.	5.8	59
20	Prevalence and significance of methicillin-resistant stapHylococcus aureus in patients with cystic fibrosis. Pediatric Pulmonology, 1988, 4, 159-163.	2.0	54
21	Macrolide resistance: an increasing concern for treatment failure in children. Pediatric Infectious Disease Journal, 2003, 22, S131-S138.	2.0	53
22	Transcriptome Remodeling of Acinetobacter baumannii during Infection and Treatment. MBio, 2017, 8, .	4.1	53
23	Rapid Molecular Diagnostics, Antibiotic Treatment Decisions, and Developing Approaches to Inform Empiric Therapy: PRIMERS I and II. Clinical Infectious Diseases, 2016, 62, 181-189.	5.8	52
24	Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	52
25	Topical fluoroquinolones: Antimicrobial activity andin vitrocorneal epithelial toxicity. Current Eye Research, 1991, 10, 557-563.	1.5	51
26	Review of current transfusion therapy and blood banking practices. Blood Reviews, 2019, 38, 100593.	5.7	49
27	Activity of Quinolones Against Mycobacteria. Drugs, 1999, 58, 19-22.	10.9	48
28	Susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 17 oral antimicrobial agents based on pharmacodynamic parameters: 1998â€“2001 U.S. Surveillance Study. Clinics in Laboratory Medicine, 2004, 24, 503-530.	1.4	48
29	Streptococcus pneumoniae: Epidemiology and patterns of resistance. The American Journal of Medicine: Supplement, 2004, 117, 3-15.	1.6	47
30	Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine. Diagnostic Microbiology and Infectious Disease, 2014, 80, 19-25.	1.8	45
31	In Vitro Activity of the New Quinolone WCK 771 against Staphylococci. Antimicrobial Agents and Chemotherapy, 2004, 48, 3338-3342.	3.2	42
32	Multicenter Clinical Evaluation of BacT/Alert Virtuo Blood Culture System. Journal of Clinical Microbiology, 2017, 55, 2413-2421.	3.9	42
33	Methylfolate Trap Promotes Bacterial Thymineless Death by Sulfa Drugs. PLoS Pathogens, 2016, 12, e1005949.	4.7	42
34	Enhancement of a culture-based bacterial detection system (eBDS) for platelet products based on measurement of oxygen consumption. Transfusion, 2005, 45, 984-993.	1.6	40
35	Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771. Expert Opinion on Pharmacotherapy, 2006, 7, 1957-1966.	1.8	38
36	Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single Î²-lactamases. Diagnostic Microbiology and Infectious Disease, 2015, 82, 65-69.	1.8	38

#	Article	IF	Citations
37	Nosocomial Outbreak of Extensively Drug-Resistant Acinetobacter baumannii Isolates Containing bla _{OXA-237} Carried on a Plasmid. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	38
38	Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV. Clinical Infectious Diseases, 2019, 68, 1823-1830.	5.8	37
39	Extensively Drug-Resistant Pseudomonas aeruginosa Isolates Containing bla _{VIM-2} and Elements of Salmonella Genomic Island 2: a New Genetic Resistance Determinant in Northeast Ohio. Antimicrobial Agents and Chemotherapy, 2014, 58, 5929-5935.	3.2	34
40	Fluoroquinolones as Chemotherapeutics Against Mycobacterial Infections. Current Pharmaceutical Design, 2004, 10, 3213-3220.	1.9	33
41	Molecular Diversity and Plasmid Analysis of KPC-Producing Escherichia coli. Antimicrobial Agents and Chemotherapy, 2016, 60, 4073-4081.	3.2	33
42	Whole-Genome Comparative Analysis of Two Carbapenem-Resistant ST-258Klebsiella pneumoniaeStrains Isolated during a North-Eastern Ohio Outbreak: Differences within the High Heterogeneity Zones. Genome Biology and Evolution, 2016, 8, 2036-2043.	2.5	28
43	Rapid Replacement of Acinetobacter baumannii Strains Accompanied by Changes in Lipooligosaccharide Loci and Resistance Gene Repertoire. MBio, 2019, 10, .	4.1	28
44	Benefit-risk Evaluation for Diagnostics: A Framework (BED-FRAME). Clinical Infectious Diseases, 2016, 63, 812-817.	5.8	27
45	Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics To Identify Susceptibility and Resistance to Carbapenems against Acinetobacter spp. in PRIMERS III. Journal of Clinical Microbiology, 2017, 55, 134-144.	3.9	26
46	Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	26
47	Activity of Quinolones against Mycobacteria. Drugs, 1995, 49, 67-75.	10.9	25
48	Antimicrobial resistance among pediatric respiratory tract infections: clinical challenges. Seminars in Pediatric Infectious Diseases, 2004, 15, 5-20.	1.7	25
49	Telithromycin post-antibiotic and post-antibiotic sub-MIC effects for 10 Gram-positive cocci. Journal of Antimicrobial Chemotherapy, 2003, 52, 809-812.	3.0	24
50	Oral Î²-lactams applied to uncomplicated infections of skin and skin structures. Diagnostic Microbiology and Infectious Disease, 2007, 57, S55-S65.	1.8	24
51	Community-Acquired Pyelonephritis in Pregnancy Caused by KPC-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2015, 59, 4375-4378.	3.2	24
52	Complete Sequence of a bla _{KPC} -Harboring Cointegrate Plasmid Isolated from Escherichia coli. Antimicrobial Agents and Chemotherapy, 2015, 59, 2956-2959.	3.2	23
53	Complete Genome Sequence of a Parabacteroides distasonis Strain (CavFT hAR46) Isolated from a Gut Wall-Cavitating Microlesion in a Patient with Severe Crohnâ€™s Disease. Microbiology Resource Announcements, 2019, 8, .	0.6	22
54	Evaluation of Etest for Susceptibility Testing of Mycobacterium tuberculosis. Journal of Clinical Microbiology, 2000, 38, 3834-3836.	3.9	21

#	Article	IF	Citations
55	A Î³-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli. Journal of Medicinal Chemistry, 2020, 63, 5990-6002.	6.4	20
56	Nasopharyngeal Carriage of Respiratory Pathogens in Children Undergoing Pressure Equalization Tube Placement in the Era of Pneumococcal Protein Conjugate Vaccine Use. Laryngoscope, 2007, 117, 295-298.	2.0	19
57	Release of complement regulatory proteins from ocular surface cells in infections. Current Eye Research, 2000, 21, 856-866.	1.5	18
58	AbGRI4, a novel antibiotic resistance island in multiply antibiotic-resistant Acinetobacter baumannii clinical isolates. Journal of Antimicrobial Chemotherapy, 2020, 75, 2760-2768.	3.0	18
59	Activity of nitazoxanide and tizoxanide against Mycobacterium tuberculosis inÂvitro and in whole blood culture. Tuberculosis, 2016, 98, 92-96.	1.9	17
60	Failure to Communicate: Transmission of Extensively Drug-Resistantbla_{OXA-237}-ContainingAcinetobacter baumanniiâ€”Multiple Facilities in Oregon, 2012â€“2014. Infection Control and Hospital Epidemiology, 2017, 38, 1335-1341.	1.8	17
61	SISPA-Seq for rapid whole genome surveys of bacterial isolates. Infection, Genetics and Evolution, 2015, 32, 191-198.	2.3	16
62	Bacterial contamination and septic transfusion reaction rates associated with platelet components before and after introduction of primary culture: experience at a US Academic Medical Center 1991 through 2017. Transfusion, 2020, 60, 974-985.	1.6	16
63	Effects of Various Test Media on the Activities of 21 Antimicrobial Agents against Haemophilus influenzae. Journal of Clinical Microbiology, 2002, 40, 3269-3276.	3.9	15
64	Synergy of amoxycillin combined with clavulanate and YTR 830 in experimental infections in mice. Journal of Antimicrobial Chemotherapy, 1986, 18, 271-276.	3.0	14
65	Prevention of otitis media: Role of pneumococcal conjugate vaccines in reducing incidence and antibiotic resistance. Journal of Pediatrics, 2002, 141, 287-293.	1.8	14
66	Association of Laboratory Methods, Colonization Density, and Age With Detection of Streptococcus pneumoniae in the Nasopharynx. American Journal of Epidemiology, 2019, 188, 2110-2119.	3.4	14
67	A Î³-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.. European Journal of Medicinal Chemistry, 2021, 220, 113436.	5.5	14
68	Genomic heterogeneity underlies multidrug resistance in Pseudomonas aeruginosa: A population-level analysis beyond susceptibility testing. PLoS ONE, 2022, 17, e0265129.	2.5	13
69	Activity of HMR 3647 Compared to Those of Six Compounds against 235 Strains of Enterococcus faecalis. Antimicrobial Agents and Chemotherapy, 1999, 43, 166-168.	3.2	12
70	The Changing Role of the Clinical Microbiology Laboratory in Defining Resistance in Gram-negatives. Infectious Disease Clinics of North America, 2016, 30, 323-345.	5.1	12
71	A two-part phase 1 study to establish and compare the safety and local tolerability of two nasal formulations of XF-73 for decolonisation of Staphylococcus aureus: A previously investigated 0.5 mg/g viscosified gel formulation versus a modified formulation. Journal of Global Antimicrobial Resistance, 2020, 21, 171-180.	2.2	12
72	Emergence of Resistance to Colistin During the Treatment of Bloodstream Infection Caused by Klebsiella pneumoniae Carbapenemaseâ€“Producing Klebsiella pneumoniae. Open Forum Infectious Diseases, 2018, 5, ofy054.	0.9	11

#	Article	IF	Citations
73	ARGONAUT II Study of the In Vitro Activity of Plazomicin against Carbapenemase-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	11
74	Mechanisms of resistance among respiratory tract pathogens. Clinics in Laboratory Medicine, 2004, 24, 419-453.	1.4	10
75	Identification of Occult Fusobacterium nucleatum Central Nervous System Infection by Use of PCR-Electrospray Ionization Mass Spectrometry. Journal of Clinical Microbiology, 2014, 52, 3462-3464.	3.9	9
76	Antimicrobial activity and in vitro corneal epithelial toxicity of antimicrobial agents for Gram-positive corneal pathogens. Current Eye Research, 1993, 12, 603-608.	1.5	8
77	Imipenem/Relebactam Resistance in Clinical Isolates of Extensively Drug Resistant Pseudomonas aeruginosa: Inhibitor-Resistant Î²-Lactamases and Their Increasing Importance. Antimicrobial Agents and Chemotherapy, 2022, 66, e0179021.	3.2	8
78	AAI101, a Novel Î²-Lactamase Inhibitor: Microbiological and Enzymatic Profiling. Open Forum Infectious Diseases, 2017, 4, S375-S375.	0.9	7
79	Streptococcus pneumoniae: Activity of newer agents against penicillin-resistant strains. Current Infectious Disease Reports, 1999, 1, 13-21.	3.0	6
80	Sulfamethoxazole Susceptibility of Mycobacterium tuberculosis Isolates from HIV-Infected Ugandan Adults with Tuberculosis Taking Trimethoprim-Sulfamethoxazole Prophylaxis. Antimicrobial Agents and Chemotherapy, 2015, 59, 5844-5846.	3.2	6
81	Recent advances in rapid antimicrobial susceptibility testing systems. Expert Review of Molecular Diagnostics, 2021, 21, 563-578.	3.1	6
82	Clinafloxacin Antibacterial Activity. Drugs, 1999, 58, 217-221.	10.9	3
83	Extended release amoxicillin/clavulanate: optimizing a product for respiratory infections based on pharmacodynamic principles. Expert Review of Anti-Infective Therapy, 2005, 3, 353-360.	4.4	3
84	Postantibiotic Effect of Levofloxacin Against Pneumococci. Drugs, 1999, 58, 378-380.	10.9	2
85	Accuracy of Direct Antimicrobial Susceptibility Testing of Gram-Negative Bacteria from Positive Blood Cultures Using MicroScan System and Value of Using Expert Rules for Î²-Lactam Agents. Antimicrobial Agents and Chemotherapy, 2022, 66, aac0214821.	3.2	2
86	Multicenter Evaluation of the Acuitas Â® AMR Gene Panel for Detection of an Extended Panel of Antimicrobial Resistance Genes among Bacterial Isolates. Journal of Clinical Microbiology, 2022, , JCM0209821.	3.9	2
87	Antianaerobic Activity of Gatifloxacin. Drugs, 1999, 58, 113-116.	10.9	1
88	Prolonged Course of Salmonella Pelvic Osteomyelitis in an Immunocompetent African American Child: A Case Report and Review of the Literature. Journal of Pediatric Infectious Diseases, 2018, 13, 084-088.	0.2	1
89	Detection of mcr-1 gene in a clinical Escherichia coli strain in North Carolina: first report. Journal of Global Antimicrobial Resistance, 2021, 25, 154-156.	2.2	1
90	Levofloxacin and Clarithromycin Antipneumococcal Activity. Drugs, 1999, 58, 366-368.	10.9	0

#	Article	IF	Citations
91	Antipneumococcal Activity of Gatifloxacin by Time-Kill Methodology. Drugs, 1999, 58, 369-371.	10.9	0
92	Antipneumococcal Activity of Gatifloxacin by Agar Dilution MIC. Drugs, 1999, 58, 372-373.	10.9	0